NIH Offers New Cell Therapy to Fight HPV Warts
Published Date: 7/16/2026
Notice
Summary
The National Cancer Institute has created a new way to make special immune cells called PILs that can fight chronic HPV infections causing painful growths in the throat and genital areas. This new cell therapy could reduce the need for repeated surgeries, improving patients’ lives and cutting healthcare costs. Researchers are now looking for partners to help develop and license this promising treatment soon.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Potential New Therapy for Chronic HPV 6/11
Researchers at the National Cancer Institute developed papilloma-infiltrating lymphocytes (PILs) to treat chronic human papillomavirus (HPV) type 6 or 11 infections that cause recurrent respiratory papillomatosis (RRP) and anogenital condyloma. This approach could reduce the need for repeated surgical debulking or laser ablation, improve quality of life, and cut ongoing healthcare costs for patients with chronic HPV 6/11 infections.
License and Co-Development Opportunity for Biotech
The National Cancer Institute is seeking industry partners to license and co-develop PIL cell therapy for HPV 6/11 conditions; the technology is at pre-clinical (in vivo validation) stage and carries NIH Reference Number E-143-2024-0. A PCT patent application was filed on October 20, 2025 (PCT/US2025/051640), and interested biotech firms focused on T cell therapies are invited to pursue licensing or collaboration.
RRP Drug Development May Qualify for Incentives
The notice states drug development for recurrent respiratory papillomatosis (RRP) may qualify for regulatory incentives due to the rarity of the disease. Sponsors developing PIL-based therapies for RRP could be eligible for such incentives during clinical development and regulatory review.
Method Could Enable Broader Non‑Cancer Treatments
The NCI reports the PIL manufacturing method can isolate and expand antigen-specific lymphocytes from non-cancerous papilloma tissue, potentially enabling adoptive cell therapies for a broader range of non-malignant diseases and supporting generation of T cell receptor (TCR) libraries for research and therapeutic use.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14346 — Government Owned Invention Available for License: Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy
The National Cancer Institute has invented a cool new way to grow special immune cells called TCR-T cells that can better fight cancer. This method helps companies make more powerful, targeted cell therapies by boosting the right cells and cutting out the extras. If you’re in biotech or cancer treatment, this is your chance to license a game-changing tool that could speed up cancer cures and bring new treatments to patients faster.
2026-14242 — National Institute on Minority Health and Health Disparities; Notice of Partially Closed Meeting
The National Institute on Minority Health and Health Disparities is holding a virtual meeting on August 31, 2026, to discuss important health topics and review grant applications. The first part of the meeting is open to the public and will be streamed online, while the last hour is closed to protect private info and trade secrets. This meeting affects researchers and communities focused on minority health and could influence future funding decisions.
2026-14133 — Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering new, powerful antibodies for licensing that help the immune system fight cancer better by releasing its natural brakes. This opportunity is perfect for companies ready to bring cutting-edge cancer treatments to market faster, with some international patent options available. Interested parties should act soon to explore this exciting tech and start making a difference—and money!
2026-14001 — National Human Genome Research Institute; Notice of Meeting
The National Human Genome Research Institute is holding a public meeting on September 28-29, 2026, to share updates and review grant applications. Scientists, researchers, and anyone interested in human genetics can join in person or online. This meeting helps decide which projects get funding, so it impacts future research and innovation in genetics.
2026-14003 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late July 2026 to review and decide on important research grant applications. These meetings keep sensitive info private, protecting ideas and personal details. Scientists applying for grants and the research community will feel the impact as funding decisions get made on time.
2026-13802 — Government Owned Invention Available for License: Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2
The National Institutes of Health is offering special mouse strains that help study a rare heart rhythm disorder called CPVT. These mice let scientists explore how a key heart gene works and test new gene therapies. Researchers interested in this tool can access it now—no patents, just pure science ready to speed up discoveries!
Previous / Next Documents
Previous: 2026-14346 — Government Owned Invention Available for License: Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy
The National Cancer Institute has invented a cool new way to grow special immune cells called TCR-T cells that can better fight cancer. This method helps companies make more powerful, targeted cell therapies by boosting the right cells and cutting out the extras. If you’re in biotech or cancer treatment, this is your chance to license a game-changing tool that could speed up cancer cures and bring new treatments to patients faster.
Next: 2026-14349 — Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Grazing Management: Range Improvement Agreements and Permits Materials
The Bureau of Land Management wants to keep collecting info about grazing permits and improvements on public lands, making sure the paperwork stays clear and easy. Ranchers and land users are affected, but no big changes or costs are expected. You’ve got until August 17, 2026, to share your thoughts and help keep things smooth and simple!